Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three‐dimensional conformal radiation therapy

BACKGROUND The detection of perineural invasion (PNI) in the diagnostic transrectal biopsy of the prostate is associated with a 93% frequency of extracapsular disease extension in patients treated by prostatectomy for adenocarcinoma of the prostate. Extracapsular extension is associated with an infe...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1997-01, Vol.79 (1), p.75-80
Main Authors: Bonin, Steven R., Hanlon, Alexandra L., Lee, W. Robert, Movsas, Benjamin, Al‐Saleem, T. I., Hanks, Gerald E.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Analysis of Variance
Biological and medical sciences
Biomarkers, Tumor - blood
extracapsular extension
Humans
Male
Medical sciences
Middle Aged
Neoplasm Invasiveness
Nephrology. Urinary tract diseases
perineural invasion
Peripheral Nervous System Neoplasms - secondary
Prostate
prostate carcinoma
prostate specific antigen
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
Prostatic Neoplasms - surgery
radiation therapy
Treatment Failure
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The detection of perineural invasion (PNI) in the diagnostic transrectal biopsy of the prostate is associated with a 93% frequency of extracapsular disease extension in patients treated by prostatectomy for adenocarcinoma of the prostate. Extracapsular extension is associated with an inferior outcome compared with that of patients who have organ‐confined disease. This study examined the association of PNI and treatment failure in a consecutive series of patients treated with three‐dimensional conformal radiation therapy (3DCRT) alone. METHODS The authors report actuarial biochemical no evidence of disease (bNED) survival rates for 484 consecutive patients with clinically localized prostate carcinoma diagnosed by transrectal needle biopsy who completed 3DCRT alone between May 1989 and December 1994. The median follow‐up time was 28 months (range, 2‐75 months), and the median dose to the center of the prostate was 7368 centigray (cGy) (range, 6316‐8074 cGy). Patients were subdivided into 2 groups according to pretreatment prostate specific antigen (PSA) levels (
ISSN:0008-543X
1097-0142
DOI:10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3